ROPIVACAINE

Ropivacaine was approved by the U.S. Food and Drug Administration (FDA) on September 26, 1996. It is a local anesthetic containing ropivacaine as its active ingredient and belongs to the amide class of anesthetic medications. It is used primarily to produce local or regional anesthesia during medical procedures.

Ropivacaine is a medication used to numb a specific area of the body, preventing pain signals from reaching the brain and providing temporary pain relief during medical procedures or surgeries.

Ropivacaine will be administered to you by a healthcare professional in a hospital setting. The part of the body where it will be used will depend on why you are being given. Do not self-administer. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors.

The most common side effects of Ropivacaine are sleepiness, trouble concentrating, dry mouth, dizziness, increase in appetite, drowsiness, and headache. Serious side effects while taking Ropivacaine are shortness of breath, wheezing, swelling of face, lips, tongue, or other parts of the body, and rash.

Do not take Ropivacaine if you are allergic to Ropivacaine, other amide-type local anesthetics, or any of its ingredients. Avoid using this medicine during intravenous regional anesthesia or obstetric paracervical anesthesia. Do not use this medicine if you are diagnosed with hypovolemia, where a decrease in blood volume could result in a drop in blood pressure.

Before starting the treatment, inform your physician if you have been using Ropivacaine, and exercise caution against direct blood vessel injections to prevent immediate toxicity. Avoid injecting inflamed areas. Inform your doctor of age-related health concerns, heart problems, advanced liver or severe kidney issues, or acute porphyria. Adjustments to the Ropivacaine Altan dose may be necessary based on these conditions. If you or your family has a history of porphyria, alternate anesthetic methods might be considered. This medicine should cautiously used in premature infants, newborns, and children under 12, as its effects and suitable injections for these groups are not well understood. Report to your doctor if you are on a salt-controlled diet before taking the injection.

Patients with liver or kidney disease should use Ropivacaine with caution and must inform their doctor of all underlying medical conditions. Do not discontinue this medicine without your doctor's advice. Unless your doctor recommends otherwise, do not breastfeed while receiving this injection. Report any serious side effects to your doctor immediately. Your doctor will determine if dose adjustments are necessary. Follow the dosage and administration instructions provided by your healthcare professional precisely. Inform your doctor of any known allergies or existing medical conditions prior to receiving Ropivacaine. If you experience unexpected or severe side effects such as difficulty breathing or allergic reaction, seek immediate medical attention. Inform your healthcare professional of all other medications or supplements you are taking to prevent potential drug interactions. Discuss any concerns about your treatment with your healthcare professional.

Boehringer Ingelheim International GmbH, Electronic medicines compendium (emc), [Revised on Feb 2023] [Accessed 22nd August 2023], pil.5073.pdf (medicines.org.uk) Boehringer Ingelheim Pharmaceuticals, Inc., US Food and Drug Administration, [ Revised on Oct 2015] [ Accessed on 22nd August 2023], PRAXBIND (Ropivacaine) injection, for intravenous use (fda.gov) James L. Zehnder, Drugs Used in Disorders of Coagulation, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 608-625.